ME03755B - Kompozicije za inhibiciju masp-2 zavisne aktivacije komplementa - Google Patents

Kompozicije za inhibiciju masp-2 zavisne aktivacije komplementa

Info

Publication number
ME03755B
ME03755B MEP-2020-121A MEP2020121A ME03755B ME 03755 B ME03755 B ME 03755B ME P2020121 A MEP2020121 A ME P2020121A ME 03755 B ME03755 B ME 03755B
Authority
ME
Montenegro
Prior art keywords
acitivation
compositions
dependent complement
inhibiting masp
masp
Prior art date
Application number
MEP-2020-121A
Other languages
German (de)
English (en)
French (fr)
Inventor
Thomas Dudler
Wayne Gombotz
James Parent
Clark Tedford
Anita Kavlie
Urs Hagemann
Herald Reiersen
Sergej Kiprijanov
Original Assignee
Omeros Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47090380&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ME03755(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Omeros Corp filed Critical Omeros Corp
Publication of ME03755B publication Critical patent/ME03755B/me

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21104—Mannan-binding lectin-associated serine protease-2 (3.4.21.104)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/53—Hinge
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/54—F(ab')2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
MEP-2020-121A 2011-05-04 2012-05-04 Kompozicije za inhibiciju masp-2 zavisne aktivacije komplementa ME03755B (me)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161482567P 2011-05-04 2011-05-04
PCT/US2012/036509 WO2012151481A1 (en) 2011-05-04 2012-05-04 Compositions for inhibiting masp-2 dependent complement acitivation
EP12779347.9A EP2704743B1 (en) 2011-05-04 2012-05-04 Compositions for inhibiting masp-2 dependent complement acitivation

Publications (1)

Publication Number Publication Date
ME03755B true ME03755B (me) 2021-04-20

Family

ID=47090380

Family Applications (1)

Application Number Title Priority Date Filing Date
MEP-2020-121A ME03755B (me) 2011-05-04 2012-05-04 Kompozicije za inhibiciju masp-2 zavisne aktivacije komplementa

Country Status (25)

Country Link
US (6) US9011860B2 (me)
EP (2) EP2704743B1 (me)
JP (5) JP5891298B2 (me)
KR (3) KR101641057B1 (me)
CN (2) CN103687620B (me)
AU (1) AU2012250627B2 (me)
BR (1) BR112013028429B1 (me)
CA (3) CA3131223C (me)
CL (1) CL2013003140A1 (me)
CY (1) CY1123212T1 (me)
DK (1) DK2704743T3 (me)
ES (1) ES2795667T3 (me)
HR (1) HRP20200887T1 (me)
HU (1) HUE049154T2 (me)
IL (4) IL229208B (me)
LT (1) LT2704743T (me)
ME (1) ME03755B (me)
MX (3) MX361175B (me)
PL (1) PL2704743T3 (me)
PT (1) PT2704743T (me)
RS (1) RS60541B1 (me)
RU (3) RU2636038C2 (me)
SI (1) SI2704743T1 (me)
WO (1) WO2012151481A1 (me)
ZA (1) ZA201308943B (me)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3689912A1 (en) 2007-09-26 2020-08-05 Chugai Seiyaku Kabushiki Kaisha Method of modifying isoelectric point of antibody via amino acid substitution in cdr
EP4238993A3 (en) 2008-04-11 2023-11-29 Chugai Seiyaku Kabushiki Kaisha Antigen-binding molecule capable of binding to two or more antigen molecules repeatedly
SG190727A1 (en) 2010-11-30 2013-07-31 Chugai Pharmaceutical Co Ltd Antigen-binding molecule capable of binding to plurality of antigen molecules repeatedly
KR20220044616A (ko) 2011-04-08 2022-04-08 유니버시티 오브 레스터 Ｍａｓｐ-2 의존적 보체 활성화와 관련된 질병을 치료하는 방법
US9644035B2 (en) 2011-04-08 2017-05-09 Omeros Corporation Methods for treating conditions associated with MASP-2 dependent complement activation
EP2704743B1 (en) * 2011-05-04 2020-03-11 Omeros Corporation Compositions for inhibiting masp-2 dependent complement acitivation
JP6774164B2 (ja) 2012-08-24 2020-10-21 中外製薬株式会社 マウスＦｃγＲＩＩ特異的Ｆｃ抗体
WO2014066744A2 (en) 2012-10-25 2014-05-01 True North Therapeutics, Inc. Anti-complement c1s antibodies and uses thereof
RS63212B1 (sr) 2012-11-02 2022-06-30 Bioverativ Usa Inc Antikomplementna c1s antitela i njihove primene
US20150017162A1 (en) 2013-03-15 2015-01-15 Omeros Corporation Methods of Generating Bioactive Peptide-bearing Antibodies and Compositions Comprising the Same
US20140363433A1 (en) 2013-03-15 2014-12-11 Omeros Corporation Methods of Generating Bioactive Peptide-bearing Antibodies and Compositions Comprising the Same
WO2014163101A1 (ja) 2013-04-02 2014-10-09 中外製薬株式会社 Ｆｃ領域改変体
CN111588855A (zh) * 2013-10-17 2020-08-28 奥默罗斯公司 用于治疗与masp-2依赖性补体活化有关的病况的方法
TWI808330B (zh) 2014-12-19 2023-07-11 日商中外製藥股份有限公司 抗肌抑素之抗體、含變異Fc區域之多胜肽及使用方法
TW202248212A (zh) 2015-02-05 2022-12-16 日商中外製藥股份有限公司 包含離子濃度依賴之抗原結合域的抗體、Fc區變體、IL-8結合抗體與其用途
PT3280440T (pt) 2015-04-06 2023-02-14 Bioverativ Usa Inc Anticorpos anti-c1s humanizados e métodos de utilização destes
CN106699888B (zh) * 2015-07-28 2020-11-06 上海昀怡健康科技发展有限公司 一种pd-1抗体及其制备方法和应用
EP3394098A4 (en) 2015-12-25 2019-11-13 Chugai Seiyaku Kabushiki Kaisha ANTI-MYOSTATIN ANTIBODIES AND METHODS OF USE
CA3185172A1 (en) * 2016-01-05 2017-07-13 Omeros Corporation Methods for inhibiting fibrosis in a subject in need thereof
WO2017173290A1 (en) 2016-03-31 2017-10-05 Omeros Corporation Methods for inhibiting angiogenesis in a subject in need thereof
JOP20170154B1 (ar) * 2016-08-01 2023-03-28 Omeros Corp تركيبات وطرق لتثبيط masp-3 لعلاج أمراض واضطرابات مختلفة
EP3494991A4 (en) 2016-08-05 2020-07-29 Chugai Seiyaku Kabushiki Kaisha COMPOSITION FOR PREVENTING OR TREATING DISEASES RELATING TO IL-8
JOP20170170B1 (ar) * 2016-08-31 2022-09-15 Omeros Corp صيغ لجسم مضاد تثبيطية لـ masp-2 بتركيز عالي ولزوجة منخفضة وأطقم، وطرق
SG10201607778XA (en) 2016-09-16 2018-04-27 Chugai Pharmaceutical Co Ltd Anti-Dengue Virus Antibodies, Polypeptides Containing Variant Fc Regions, And Methods Of Use
JOP20190068A1 (ar) * 2016-10-13 2019-04-01 Omeros Corp طرق لتقليل البول البروتيني في خاضع بشري يعاني من الاعتلال الكلوي a الناتج عن الجلوبيولين المناعي
TWI818919B (zh) * 2017-08-15 2023-10-21 美商歐米諾斯公司 用於治療和／ 或預防與造血幹細胞移植有關的移植物抗宿主病和／ 或瀰漫性肺泡出血和／ 或靜脈閉塞性病的方法
TWI827585B (zh) 2018-03-15 2024-01-01 日商中外製藥股份有限公司 對茲卡病毒具有交叉反應性的抗登革病毒抗體及其使用方法
US11584714B2 (en) 2018-05-29 2023-02-21 Omeros Corporation MASP-2 inhibitors and methods of use
SG11202010925UA (en) * 2018-05-29 2020-12-30 Omeros Corp Masp-2 inhibitors and methods of use
MX2021006864A (es) * 2018-12-13 2021-07-02 Argenx Bvba Anticuerpos contra el factor c2b del complemento humano y metodos de uso.
EP4069238A1 (en) 2019-12-04 2022-10-12 Omeros Corporation Masp-2 inhibitors and methods of use
CA3159159A1 (en) 2019-12-04 2021-06-10 Neil S. Cutshall Masp-2 inhibitors and methods of use
IL293550A (en) * 2019-12-04 2022-08-01 Omeros Corp 2-masp inhibitor compounds, preparations containing them and their uses
JP2023504542A (ja) 2019-12-04 2023-02-03 オメロス コーポレーション Ｍａｓｐ－２阻害剤および使用方法
TW202319069A (zh) * 2020-03-06 2023-05-16 美商奥默羅斯公司 用於治療和/或預防流感病毒誘導的急性呼吸窘迫症候群、肺炎或者流感病毒感染的一些其它肺部表現的抑制masp-2的方法
CN114634575A (zh) * 2020-12-16 2022-06-17 康诺亚生物医药科技（成都）有限公司 一种补体抑制剂的开发和应用
CA3206789A1 (en) * 2021-02-05 2022-08-11 Gregory A. Demopulos Biomarker for assessing the risk of developing acute covid-19 and post-acute covid-19
CN115215937B (zh) * 2021-04-15 2023-05-26 上海麦济生物技术有限公司 抗人masp-2抗体及其制备方法和应用
BR112023020622A2 (pt) 2021-04-25 2023-12-05 Jiangsu Hengrui Pharmaceuticals Co Ltd Anticorpo anti-masp2, fragmento de ligação ao antígeno do mesmo e uso médico do mesmo
WO2023103789A1 (zh) * 2021-12-10 2023-06-15 舒泰神（北京）生物制药股份有限公司 特异性识别masp2的抗体及其应用
US20230265215A1 (en) * 2021-12-10 2023-08-24 Omeros Corporation Therapeutic antibodies that bind to the serine protease domain of masp-2 and uses thereof
CN116284412A (zh) * 2021-12-21 2023-06-23 沈阳三生制药有限责任公司 一种抗masp-2抗体及其制备方法与用途
WO2023174039A1 (en) * 2022-03-18 2023-09-21 Inmagene Biopharmaceuticals (Hangzhou) Co., Ltd. Masp-2-targetting antibodies and uses thereof

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5211657A (en) 1988-11-07 1993-05-18 The United States Government As Represented By The Secretary Of The Department Of Health And Human Services Laminin a chain deduced amino acid sequence, expression vectors and active synthetic peptides
US5549910A (en) 1989-03-31 1996-08-27 The Regents Of The University Of California Preparation of liposome and lipid complex compositions
US5859205A (en) * 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
JP3218637B2 (ja) 1990-07-26 2001-10-15 大正製薬株式会社 安定なリポソーム水懸濁液
JP2958076B2 (ja) 1990-08-27 1999-10-06 株式会社ビタミン研究所 遺伝子導入用多重膜リポソーム及び遺伝子捕捉多重膜リポソーム製剤並びにその製法
US5856121A (en) 1994-02-24 1999-01-05 Case Western Reserve University Growth arrest homebox gene
JPH07238100A (ja) 1994-02-25 1995-09-12 Sumitomo Electric Ind Ltd ヒトのｍａｓｐに対するモノクローナル抗体
US5741516A (en) 1994-06-20 1998-04-21 Inex Pharmaceuticals Corporation Sphingosomes for enhanced drug delivery
JPH10510540A (ja) 1994-12-12 1998-10-13 オメロス メディカル システムズ，インコーポレーテッド 灌注用溶液並びに疼痛、炎症及びけいれんの抑制法
US5795587A (en) 1995-01-23 1998-08-18 University Of Pittsburgh Stable lipid-comprising drug delivery complexes and methods for their production
US5738868A (en) 1995-07-18 1998-04-14 Lipogenics Ltd. Liposome compositions and kits therefor
US7083786B2 (en) 1997-04-03 2006-08-01 Jensenius Jens Chr MASP-2, a complement-fixing enzyme, and uses for it
JP2002532079A (ja) 1998-12-15 2002-10-02 ザ ブライハム アンド ウイミンズ ホスピタル， インコーポレイテッド 補体活性化に関連するレクチン補体経路を調節するための方法および産物
ES2308985T3 (es) 1999-07-21 2008-12-16 Omeros Corporation Disoluciones y procedimientos para la inhibicion del dolor, inflamacion y degradacion del cartilago.
US20010051754A1 (en) 1999-08-03 2001-12-13 Daria N. Lissy Plural stage toluene disproportionation process minimizing ethylbenzene
DK1259547T3 (da) * 2000-03-01 2012-10-15 Medimmune Inc Højpotente, rekombinante antistoffer og fremgangsmåde til fremstilling heraf
SG98393A1 (en) 2000-05-19 2003-09-19 Inst Materials Research & Eng Injectable drug delivery systems with cyclodextrin-polymer based hydrogels
DE60139072D1 (de) 2000-07-13 2009-08-06 Helion Biotech Aps Masp-2, ein komplement fixierendes enzym, und dessen verwendungen
ES2288900T3 (es) 2001-10-05 2008-02-01 Affimed Therapeutics Ag Anticuerpo de origen humano para inhibir la agregacion de trombocitos.
DK2319301T3 (en) * 2001-11-30 2017-12-04 Amgen Fremont Inc Transgenic animals with human Ig lambda light chain genes
CA2474645C (en) 2002-02-01 2011-08-09 Omeros Corporation Compositions and methods for systemic inhibition of cartilage degradation
CA2490007C (en) 2002-07-19 2011-05-24 Omeros Corporation Biodegradable triblock copolymers, synthesis methods therefor, and hydrogels and biomaterials made there from
KR20050106459A (ko) * 2003-02-28 2005-11-09 미쯔비시 웰 파마 가부시키가이샤 단일클론 항체, 이를 코딩하는 유전자, 하이브리도마, 의약조성물 및 진단 시약
SI1625166T1 (sl) 2003-05-12 2015-08-31 Helion Biotech Aps Protitelesa masp-2
WO2005123776A1 (en) 2004-06-10 2005-12-29 Omeros Corporation Methods for treating conditions associated with lectin-dependent complement activation
US7919094B2 (en) 2004-06-10 2011-04-05 Omeros Corporation Methods for treating conditions associated with MASP-2 dependent complement activation
LT1753456T (lt) * 2004-06-10 2016-11-10 Omeros Corporation Ligų, susijusių su nuo masp-2 priklausomu komplemento aktyvinimu, gydymo būdai
GB0412966D0 (en) 2004-06-10 2004-07-14 Univ Leicester Genetically modified non-human mammals and cells
US8840893B2 (en) 2004-06-10 2014-09-23 Omeros Corporation Methods for treating conditions associated with MASP-2 dependent complement activation
CA2735900A1 (en) * 2008-09-19 2010-03-25 Medimmune, Llc Antibodies directed to dll4 and uses thereof
JP2012508017A (ja) 2008-11-07 2012-04-05 ファブラス エルエルシー 抗ｄｌｌ４抗体及びその使用
JP5911804B2 (ja) 2009-10-16 2016-04-27 オメロス コーポレーション Ｍａｓｐ−２依存性の補体活性化を阻害することによって播種性血管内凝固を処置するための方法
EP2704743B1 (en) * 2011-05-04 2020-03-11 Omeros Corporation Compositions for inhibiting masp-2 dependent complement acitivation
RU2018114903A (ru) * 2012-04-06 2019-03-04 Омерос Корпорейшн Композиции и способы ингибирования masp-1, и/или masp-2, и/или masp-3 для лечения пароксизмальной ночной гемоглобинурии

Also Published As

Publication number Publication date
ZA201308943B (en) 2015-05-27
MX2018014714A (es) 2021-11-16
CN103687620B (zh) 2017-10-13
US20240092938A1 (en) 2024-03-21
JP2022172275A (ja) 2022-11-15
EP2704743A4 (en) 2014-11-05
JP2020097630A (ja) 2020-06-25
IL229208B (en) 2021-03-25
KR101641057B1 (ko) 2016-07-20
MX347691B (es) 2017-05-09
IL266756A (en) 2019-07-31
CA3131223A1 (en) 2012-11-08
RU2017137872A3 (me) 2019-04-30
US20170088632A1 (en) 2017-03-30
PL2704743T3 (pl) 2020-08-24
US10683367B2 (en) 2020-06-16
IL229208A0 (en) 2014-01-30
CL2013003140A1 (es) 2014-05-23
HRP20200887T1 (hr) 2020-09-04
JP2014515922A (ja) 2014-07-07
MX2013012862A (es) 2013-12-02
AU2012250627B2 (en) 2016-01-07
JP2018123148A (ja) 2018-08-09
KR20140006096A (ko) 2014-01-15
US11613589B2 (en) 2023-03-28
CN103687620A (zh) 2014-03-26
CA3025762C (en) 2021-11-09
IL285522A (en) 2021-09-30
EP2704743A1 (en) 2014-03-12
JP5891298B2 (ja) 2016-03-22
AU2012250627A1 (en) 2013-03-21
RU2017137872A (ru) 2019-04-30
HUE049154T2 (hu) 2020-09-28
US20120282263A1 (en) 2012-11-08
LT2704743T (lt) 2020-09-10
RS60541B1 (sr) 2020-08-31
PT2704743T (pt) 2020-06-17
CN107011443B (zh) 2021-04-30
US20190119402A1 (en) 2019-04-25
ES2795667T3 (es) 2020-11-24
CN107011443A (zh) 2017-08-04
CA3131223C (en) 2024-01-30
BR112013028429B1 (pt) 2022-11-08
DK2704743T3 (en) 2020-05-25
US9011860B2 (en) 2015-04-21
CY1123212T1 (el) 2021-10-29
EP2704743B1 (en) 2020-03-11
WO2012151481A1 (en) 2012-11-08
JP6352226B2 (ja) 2018-07-04
EP3725811A3 (en) 2021-01-27
RU2725958C2 (ru) 2020-07-07
CA2832871A1 (en) 2012-11-08
CA2832871C (en) 2019-01-15
BR112013028429A2 (pt) 2020-07-21
SI2704743T1 (sl) 2020-08-31
US10047165B2 (en) 2018-08-14
MX361175B (es) 2018-11-29
KR20180086298A (ko) 2018-07-30
RU2013153527A (ru) 2015-06-10
EP3725811A2 (en) 2020-10-21
KR20160087917A (ko) 2016-07-22
NZ715226A (en) 2017-07-28
CA3025762A1 (en) 2012-11-08
NZ733310A (en) 2021-12-24
US20160002349A1 (en) 2016-01-07
IL266756B (en) 2021-08-31
JP6669800B2 (ja) 2020-03-18
RU2636038C2 (ru) 2017-11-17
KR101882830B1 (ko) 2018-07-31
US9475885B2 (en) 2016-10-25
JP2015227380A (ja) 2015-12-17
NZ617487A (en) 2016-03-31
RU2020120539A (ru) 2021-12-23
US20210054099A1 (en) 2021-02-25
KR102024016B1 (ko) 2019-11-04

Similar Documents

Publication Publication Date Title
DK2704743T3 (en) Compositions for inhibiting masp-2 dependent complement acitivation
HK1203403A1 (en) Peracid-generating compositions
HK1192578A1 (zh) 抗結皮組合物
GB201117619D0 (en) Compositions
SG11201401335QA (en) Compositions
GB201117621D0 (en) Compositions
EP2763756A4 (en) BROMOFLUOROCARBON COMPOSITIONS
GB2496447B (en) Compositions
GB201110833D0 (en) Compositions
GB201103942D0 (en) Compositions
HK1201687A1 (en) Improved compositions
GB201110132D0 (en) compositions
GB201104849D0 (en) Compositions
GB201122213D0 (en) Compositions
GB201122216D0 (en) Compositions
GB201122214D0 (en) Compositions
GB201121028D0 (en) Compositions
GB201120406D0 (en) Compositions
GB201117234D0 (en) Compositions
GB201117165D0 (en) Compositions
GB201114629D0 (en) Compositions
GB201109121D0 (en) Compositions
GB201108338D0 (en) Compositions
GB201108040D0 (en) Compositions
GB201107998D0 (en) Compositions